Michael Reusch

POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery

Alexander Zarbock, Christian Strauß, Maxime Laflamme, Andrej Myjavec et autres

de, ca, cz, es (code pays fourni par la source)

#644 A phase 2b dose finding study to assess the efficacy of RMC-035 on renal function in participants at high risk for kidney injury following open-chest cardiac surgery (POINTER)

Alexander Zarbock, Tobias Agervald, Michael Reusch, Maxime Laflamme et autres

de, ca, cz (code pays fourni par la source)

Kidney Function Following Open-Chest Cardiac Surgery: Post Hoc Analysis of the AKITA Study

Michael Reusch, Alexander Zarbock, Tobias Agervald

us, ch (code pays fourni par la source)

Efficacy of RMC-035 in Reducing MAKE90 in Patients with and Without AKI After Cardiac Surgery: Post Hoc Analysis of the AKITA Study

Michael Reusch, Alexander Zarbock, Tobias Agervald

us, ch (code pays fourni par la source)

POINTER: A Phase 2b, Randomized, Placebo-Controlled, Double-Blind Dose-Finding Clinical Study of RMC-035 in Participants at High Risk for Kidney Injury Following Cardiac Surgery

Jay L. Koyner, Alexander Zarbock, Andrej Myjavec, Ignacio Muñoz Carvajal et autres

us, ch, cz, es, hr, de, ca (code pays fourni par la source)

Neuaufstellung der ambulanten Dermatologie in schwieriger Zeit

Michael Reusch

Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study

Johan Nordström, Lars Wennberg, Greg Nowak, Tobias E. Larsson et autres

se, us (code pays fourni par la source)

Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial

Alexander Zarbock, Tobias E. Larsson, Nicolas Noiseux, C. David Mazer et autres

de, ca, cz, us (code pays fourni par la source)

Results of a Randomized Placebo-Controlled Double-Blind Adaptive Phase 2 Study (AKITA) Evaluating RMC-035 for the Prevention of AKI in Patients Undergoing Cardiac Surgery

Alexander Zarbock, Jay L. Koyner, Andreas Boening, Daniel T. Engelman et autres

de, us, it (code pays fourni par la source)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease

Tomas Ganz, Francesco Locatelli, Mustafa Arıcı, Tadao Akizawa et autres

us, it, tr, jp (code pays fourni par la source)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

Jonathan Barratt, Frank Dellanna, José Pórtoles, Gabriel Choukroun et autres

gb, es, fr, us, rs (code pays fourni par la source)

Cardiovascular Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents for Treatment of Anemia in Patients With Chronic Kidney Disease Incident to or Not Receiving Dialysis: Pooled Subgroup Analysis of Four Phase 3 Studies

Ciro Esposito, Jonathan Barratt, Frank Dellanna, José Pórtoles et autres

it, gb, us, fr (code pays fourni par la source)